![Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update- Product Image](http://www.researchandmarkets.com/product_images/12333/12333557_500px_jpg/superoxide_dismutase_[cuzn]_drugs.jpg)
1h Free Analyst Time
According to the recently published report 'Superoxide Dismutase [Cu-Zn] - Drugs In Development, 2022'; Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.Speak directly to the analyst to clarify any post sales queries you may have.
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide (O2-) radical into either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2) which prevents damage to tissues. Superoxide dismutase is used for treating pain and swelling (inflammation) caused by osteoarthritis, sports injuries, and rheumatoid arthritis, a kidney condition called interstitial cystitis, gout, poisoning caused by a weed-killer called paraquat, cancer, and lung problems in newborns.
The report 'Superoxide Dismutase [Cu-Zn] - Drugs In Development, 2022' outlays comprehensive information on the Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal and Genetic Disorders which include indications Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Parkinson's Disease, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Wilson Disease.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)
- The report reviews Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Overview
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Companies Involved in Therapeutics Development
- AL-S Pharma AG
- Alexion Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
- Apic Bio Inc
- Avrion Therapeutics AG
- Biogen Inc
- Collaborative Medicinal Development LLC
- Novartis Gene Therapies
- ProMIS Neurosciences Inc
- ResQ Biotech
- Thera Neuropharma Inc
- Voyager Therapeutics Inc
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Drug Profiles
- ALN-SOD - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AP-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- APB-102 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AVR-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AVXS-301 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cu(II)ATSM - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NU-9 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Peptides to Inhibit Superoxide Dismutase (SOD1) for Amyotrophic Lateral Sclerosis - Drug Profile
- Product Description
- Mechanism Of Action
- RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SOD1 - Drug Profile
- Product Description
- Mechanism Of Action
- TDI-186 - Drug Profile
- Product Description
- Mechanism Of Action
- THN-1 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tiomolibdate choline - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tofersen sodium - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VYSOD-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VYSOD-102 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Dormant Products
- Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Product Development Milestones
- Featured News & Press Releases
- Jul 27, 2022: FDA grants priority review for Biogen’s tofersen to treat ALS
- Jul 26, 2022: Ionis announces that FDA accepts New Drug Application and grants priority review of tofersen for a rare, genetic form of ALS
- Jun 23, 2022: ALXN1840 shows rapid and sustained improvement in copper mobilization from tissues, potentially closing treatment gaps for Wilson Disease community
- Jun 03, 2022: Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
- Jun 03, 2022: New 12-month tofersen data presented at ENCALS meeting show clinically meaningful benefit in people with SOD1-ALS
- Nov 18, 2021: Neurimmune and TVM Capital Life Science announce the initiation of AL-S Pharma's phase 2 Study of AP-101 for the treatment of ALS
- Oct 18, 2021: Biogen’s tofersen fails to meet primary goal in Phase III ALS trial
- Oct 17, 2021: Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
- Oct 14, 2021: Topline results from Tofersen phase 3 study and its open label extension in SOD1-ALS to be presented at the American Neurological Association Annual Meeting
- Aug 27, 2021: Alexion’s drug meets primary goal in Phase III Wilson disease trial
- Jul 28, 2021: Apic Bio receives FDA fast track designation for APB-102 for the treatment of patients with SOD1 ALS
- Apr 21, 2021: Apic Bio announces FDA clearance of IND application for lead gene therapy candidate APB-102 for the treatment of SOD1 ALS
- Feb 23, 2021: ALS neuron damage reversed with new compound
- Jul 23, 2020: Investigational drug for genetic form of ALS showing early promise, trial indicates
- Jul 13, 2020: New treatment for motor neurone disease shows promise in early trials
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by AL-S Pharma AG, 2022
- Pipeline by Alexion Pharmaceuticals Inc, 2022
- Pipeline by Alnylam Pharmaceuticals Inc, 2022
- Pipeline by Apic Bio Inc, 2022
- Pipeline by Avrion Therapeutics AG, 2022
- Pipeline by Biogen Inc, 2022
- Pipeline by Collaborative Medicinal Development LLC, 2022
- Pipeline by Novartis Gene Therapies, 2022
- Pipeline by ProMIS Neurosciences Inc, 2022
- Pipeline by ResQ Biotech, 2022
- Pipeline by Thera Neuropharma Inc, 2022
- Pipeline by Voyager Therapeutics Inc, 2022
- Dormant Projects, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AL-S Pharma AG
- Alexion Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
- Apic Bio Inc
- Avrion Therapeutics AG
- Biogen Inc
- Collaborative Medicinal Development LLC
- Novartis Gene Therapies
- ProMIS Neurosciences Inc
- ResQ Biotech
- Thera Neuropharma Inc
- Voyager Therapeutics Inc
